Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment.

Kidney fibrosis is a serious consequence of chronic kidney disease (CKD), and currently, there is no effective pharmacological treatment available. Cellular communication network-2 (CCN2/CTGF) is an extracellular matrix (ECM) protein that regulates the fibrotic process by activating the epidermal growth factor receptor (EGFR) signaling pathway. We herein present the discovery and structure-activity relationship study of novel peptides targeting CCN2 to develop potent and stable specific inhibitors of the CCN2/EGFR interaction. Remarkably, the 7-mer cyclic peptide OK2 exhibited potent activities to inhibit CCN2/EGFR-induced STAT3 phosphorylation and cellular ECM protein synthesis. Subsequent in vivo studies demonstrated that OK2 significantly alleviated renal fibrosis in a unilateral ureteral obstruction (UUO) mouse model. Moreover, this study first revealed that the peptide candidate could efficiently block CCN2/EGFR interaction through binding to the CT domain of CCN2, providing a new alternative strategy for peptide-based targeting of CCN2 and modulating CCN2/EGFR-mediated biological functions in kidney fibrosis.

[1]  Xianxing Jiang,et al.  Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis. , 2023, Journal of medicinal chemistry.

[2]  A. Zarrinpar,et al.  CCN2/CTGF promotes liver fibrosis through crosstalk with the Slit2/Robo signaling , 2022, Journal of Cell Communication and Signaling.

[3]  Guangfu Li,et al.  Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy. , 2022, Journal of medicinal chemistry.

[4]  Yibin Kang,et al.  Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction. , 2022, Journal of medicinal chemistry.

[5]  A. Peier,et al.  Discovery and Structure-Based Design of Macrocyclic Peptides Targeting STUB1. , 2022, Journal of medicinal chemistry.

[6]  Youhua Liu,et al.  The fibrogenic niche in kidney fibrosis: components and mechanisms , 2022, Nature Reviews Nephrology.

[7]  R. Samarakoon,et al.  Cellular communication network 2 (connective tissue growth factor) aggravates acute DNA damage and subsequent DNA damage response-senescence-fibrosis following kidney ischemia reperfusion injury. , 2022, Kidney international.

[8]  K. Pearce,et al.  Discovery and Structural Basis of the Selectivity of Potent Cyclic Peptide Inhibitors of MAGE-A4. , 2022, Journal of medicinal chemistry.

[9]  Yuzhang Wu,et al.  Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. , 2022, Phytomedicine.

[10]  L. Hsiao,et al.  Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration. , 2022, Cell reports.

[11]  J. L. Morgado-Pascual,et al.  CCN2 Binds to Tubular Epithelial Cells in the Kidney , 2022, Biomolecules.

[12]  P. Boor,et al.  New Aspects of Kidney Fibrosis–From Mechanisms of Injury to Modulation of Disease , 2022, Frontiers in Medicine.

[13]  Xi Sun,et al.  Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis , 2021, Acta pharmaceutica Sinica. B.

[14]  B. Chaqour,et al.  The CCN2/CTGF interactome: an approach to understanding the versatility of CCN2/CTGF molecular activities , 2021, Journal of Cell Communication and Signaling.

[15]  L. Richeldi,et al.  Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials , 2021, Expert opinion on emerging drugs.

[16]  M. Walko,et al.  Peptide-based inhibitors of protein–protein interactions: biophysical, structural and cellular consequences of introducing a constraint , 2021, Chemical science.

[17]  J. Kellum,et al.  Acute kidney disease and cirrhosis. , 2020, Journal of hepatology.

[18]  Xianxing Jiang,et al.  AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis , 2020, Nature Communications.

[19]  W. Xu,et al.  A novel peptide binding to the C-terminal domain of connective tissue growth factor for the treatment of bleomycin-induced pulmonary fibrosis. , 2019, International journal of biological macromolecules.

[20]  M. Sánchez-Niño,et al.  Design and optimization strategies for the development of new drugs that treat chronic kidney disease , 2019, Expert opinion on drug discovery.

[21]  D. Pei,et al.  Understanding Cell Penetration of Cyclic Peptides. , 2019, Chemical reviews.

[22]  H. Suga,et al.  Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. , 2019, Journal of the American Chemical Society.

[23]  R. Goldschmeding,et al.  Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage , 2018, Mediators of inflammation.

[24]  V. Jha,et al.  Getting to know the enemy better-the global burden of chronic kidney disease. , 2018, Kidney international.

[25]  R. Goldschmeding,et al.  Connective tissue growth factor (CTGF) from basics to clinics. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[26]  A. Ortiz,et al.  Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation , 2018, The Journal of pathology.

[27]  Richard Obexer,et al.  Strategies for transitioning macrocyclic peptides to cell-permeable drug leads. , 2017, Current opinion in biotechnology.

[28]  B. Garcia,et al.  Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling. , 2016, Molecular cell.

[29]  L. Lau.  Cell surface receptors for CCN proteins , 2016, Journal of Cell Communication and Signaling.

[30]  M. Sternlicht,et al.  FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition , 2016, Pharmaceutical Research.

[31]  G. Raghu,et al.  FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis , 2016, European Respiratory Journal.

[32]  M. Takigawa,et al.  Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic cells in the liver. , 2014, Surgery.

[33]  R. Goldschmeding,et al.  A Perspective on Anti-ccn2 Therapy for Chronic Kidney Disease C C N 2 F U N C T I O N S I N N O R M a L P H Y S I O Lo Gy , 2022 .

[34]  W. Pao,et al.  Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer , 2013, Nature Reviews Clinical Oncology.

[35]  Y. Jeng,et al.  CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation , 2012, Cell Death and Differentiation.

[36]  Xiaobo Fan,et al.  A novel single‐chain‐Fv antibody against connective tissue growth factor attenuates bleomycin‐induced pulmonary fibrosis in mice , 2011, Respirology.

[37]  S. Zhuang,et al.  A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. , 2010, Kidney international.

[38]  K. Schmidt-Ott.  Unraveling the role of connective tissue growth factor in diabetic nephropathy. , 2008, Kidney international.

[39]  Bicheng Liu,et al.  Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[40]  K. Nakao,et al.  Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. , 2004, Journal of the American Society of Nephrology : JASN.

[41]  V. Čapkun,et al.  Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience. , 2016, Neoplasma.

[42]  A. Ortiz,et al.  The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells. , 2015, Antioxidants & redox signaling.

[43]  M. Y. Kim,et al.  Noncovalenly PEGylated CTGF siRNA/PDMAEMA complex for pulmonary treatment of bleomycin-induced lung fibrosis. , 2013, Biomaterials.